Vasa Therapeutics
↗Encinitas, USA
Vasa Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cardiovascular and metabolic aging. The company focuses on addressing the pathophysiology of diseases such as heart failure, sarcopenia, and obesity by targeting biomarkers that mediate fibroinflammatory responses, such as endotrophin.
Headquartered in Encinitas, CA, with significant R&D operations in Wroclaw, Poland, Vasa leverages a computational chemistry and design platform to discover novel small molecules and peptide analogs. Their lead candidate, VS-041, represents a personalized medicine approach to treating heart failure with preserved ejection fraction (HFpEF) by inhibiting the release of pro-fibrotic signaling fragments.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Cardiovascular Therapeutics
SIZE & FINANCIALS
Employees:1-50
Founded:2019
Ownership:private
Status:operating
FUNDING
Stage:Seed
Total Raised:$11M
Investors:Orphinic Scientific SA, NuFund Venture Group, SeedFolio, i&i Biotech Fund I
PIPELINE
Stage:Phase 1
Lead Drug Stage:Phase 1c (Proof-of-Mechanism)
Modalities:Small molecule, Peptide analog
Active Trials:1
Trial Phases:Phase 1: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Vasa Therapeutics Sp. z o.o. (Poland)
Key Partnerships:Quotient Sciences (Drug development accelerator), Polish National Centre for Research and Development (Grant funding)
COMPETITION
Position:Emerging
Competitors:Esperion Therapeutics, Kiniksa Pharmaceuticals, Tenaya Therapeutics, Kardigan
LEADERSHIP
Key Executives:
Artur Plonowski, MD, PhD - CEO & Co-founder
Noreen R. Henig, MD - Chief Medical Officer
Scientific Founders:Artur Plonowski, Christopher J. Larson, Benjamin Pratt
Board Members:Prof. Jarosław Leszczyszyn (Orphinic Scientific)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Vasa Therapeutics. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.